CoChat

Anti-fibrotic Potential of AT2 Receptor Agonists

Open access
Wang, Yan, Del Borgo, Mark, Lee, Huey W., Baraldi, Dhaniel, Hirmiz, Baydaa, Gaspari, Tracey A., Denton, Kate M., Aguilar, Marie-Isabel, Samuel, Chrishan S., Widdop, Robert E. · 2017 · Frontiers in Pharmacology
Cited by 71

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

There are a number of therapeutic targets to treat organ fibrosis that are under investigation in preclinical models. There is increasing evidence that stimulation of the angiotensin II type 2 receptor (AT2R) is a novel anti-fibrotic strategy and we have reviewed the published in vivo preclinical data relating to the effects of Compound 21 (C21), which is the only nonpeptide AT2R agonist that is currently available for use in chronic preclinical studies. In particular, the differential influence of AT2R on extracellular matrix (ECM) status in various preclinical fibrotic models is discussed, and novel in vitro data on the anti-fibrotic effects of C21 is also presented. Collectively, these studies demonstrate that pharmacological AT2R stimulation using C21 decreases organ fibrosis, which has been most studied in the setting of cardiovascular and renal disease. In addition, AT2R-mediated anti-inflammatory effects may contribute to the beneficial AT2R-mediated anti-fibrotic effects seen in preclinical models.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphar.2017.00564

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 71

Metadata

Authors
Wang, Y., Del Borgo, M., Lee, H. W., Baraldi, D., Hirmiz, B., Gaspari, T. A., Denton, K. M., Aguilar, M.-I., Samuel, C. S., & Widdop, R. E.
Venue
Frontiers in Pharmacology
Published
2017-08-31
Volume
8
Pages
564-564
ISSN
1663-9812 (ISSN-L)
OpenAlex
W2751073142
Cited by
71
References
5
FWCI
5.62
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-fibrotic Potential of AT2 Receptor Agonists. https://app.cochat.ai/papers/10.3389/fphar.2017.00564
The paper
Wang, Y., Del Borgo, M., Lee, H. W., Baraldi, D., Hirmiz, B., Gaspari, T. A., Denton, K. M., Aguilar, M.-I., Samuel, C. S., & Widdop, R. E. (2017). Anti-fibrotic Potential of AT2 Receptor Agonists. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2017.00564

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.